Procept BioRobotics receives FDA IDE to investigate Aquablation

PROCEPT BioRobotics announced the Investigational Device Exemption, IDE, approval from the U.S. Food and Drug Administration to investigate the safety and efficacy of Aquablation therapy for prostate cancer. Reza Zadno, CEO of PROCEPT BioRobotics, remarked, “Receiving IDE approval to explore Aquablation Therapy for men with localized prostate cancer marks a pivotal moment for PROCEPT. While our primary commitment is to establish ourselves as the standard of care for the treatment of BPH, we acknowledge the distinctive potential of our robotic system to address other urological indications.” Zadno added, “Our aim is to bolster the clinical evidence through this study and collaborate with some of the nation’s foremost cancer physicians.”